Oklahoma Spent $2M on a Controversial Malaria Drug

The controversial drug, ordinarily used to treat malaria patients, has been stockpiled by Oklahoma.

WASHINGTON–At least 22 states, including Oklahoma, have obtained a total of more than 10 million doses of malaria drugs to treat COVID-19 patients despite warnings from doctors that more tests are needed.

President Donald J. Trump once fiercely promoted the drug.

Oklahoma has spent millions to stockpile the controversial drug.

Most recently, Mr. Trump said he personally uses the drug.

At least 22 states and Washington, D.C., secured shipments of the drug, hydroxychloroquine, according to information compiled from state and federal officials by The Black Chronicle.

Sixteen of those states were won by Trump in 2016, although five of them, including North Carolina and Louisiana, are now led by Democratic governors.

Supporters say having a supply on hand makes sense in case the drug is shown to be effective against the pandemic that has devastated the global economy and killed nearly 200,000 people worldwide, and to ensure a steady supply for people who need it for other conditions like lupus.

But health experts worry that having the drug easily available at a time of heightened public fear could make it easier to misuse it.

The federal Food and Drug Administration last month warned doctors against prescribing the drug, hydroxychloroquine, for treating the coronavirus outside of hospitals or research settings because of reports of serious side effects, including dangerous irregular heart rhythms and death among patients.

It’s the latest admonition against the drug that President Trump mentioned 17 times in various public appearances, touting its potential despite his own health advisers telling him it is unproven.

Oklahoma spent $2 million to buy the drugs, and Utah and Ohio have spent hundreds of thousands on purchases. The rest of the cities and states received free shipments from drug companies or the U.S. government over the last month. Ohio received a large donation from a local company.

Several states, including New York, Connecticut, Oregon, Louisiana, North Carolina and Texas received donations of the medication from a private company based in New Jersey called Amneal Pharmaceutical. Florida was given 1 million doses from Israeli company Teva Pharmaceutical.

The Federal Emergency Management Agency said Friday it has sent out 14.4 million doses of hydroxychloroquine to 14 cities, including Washington, D.C., Philadelphia and Baltimore, from the federal government’s national stockpile, a source that also provided South Dakota and California with supplies. The agency said earlier this month it had sent 19 million tablets and didn’t explain the discrepancy between the two figures.

The federal government received a donation of 30 million doses from Swiss drugmaker, Novartis on, March 29 to build up the stockpile, which does not normally stock the drug.

“If he [President Trump]  hadn’t amplified the early and inappropriate enthusiasm for the drug, I doubt if the states would have even been aware of it,” said Dr. Kenneth B. Klein, a consultant from outside of Seattle, who has spent the last three decades working for drug companies to design and evaluate their clinical trials.

Dr. Klein said it’s understandable that government and health officials looked into hydroxychloroquine — which is approved for treating malaria, rheumatoid arthritis and lupus — as a possible remedy during a frightening pandemic, but the time and energy has been misspent. The potential side effects are worrisome, especially because many coronavirus patients already have underlying health conditions, he said.

“The states and the federal government are reacting in light of that fear. But it’s not a rational response,” Dr. Klein said.

Doctors can already prescribe the malaria drug to patients with COVID-19, a practice known as off-label prescribing, and many do. Medical and pharmacy groups have warned against prescribing it for preventive purposes. The FDA has allowed it into the national stockpile, but only for narrowly defined purposes as studies continue.

Utah Gov. Gary Herbert, a Republican, has previously acknowledged that the drug is “not without controversy,” but defended the state’s efforts to build up a supply. As questions mounted Friday, though, he distanced himself from an $800,000 purchase the state made from a local company and said it would be investigated.

Gov. Herbert also halted a plan to spend $8 million more to buy 200,000 additional treatments.

“The bottom line is, we’re not purchasing any more of this drug,” he said.

Follow by Email